Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H30Cl2FNO3 |
| Molecular Weight | 554.479 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=C2C(CCCC(C3=CC=C(Cl)C=C3Cl)=C2C4=CC=C(O[C@H]5CCN(CCCF)C5)C=C4)=C1
InChI
InChIKey=KISZAGQTIXIVAR-VWLOTQADSA-N
InChI=1S/C31H30Cl2FNO3/c32-23-8-12-27(29(33)18-23)28-4-1-3-21-17-22(31(36)37)7-11-26(21)30(28)20-5-9-24(10-6-20)38-25-13-16-35(19-25)15-2-14-34/h5-12,17-18,25H,1-4,13-16,19H2,(H,36,37)/t25-/m0/s1
| Molecular Formula | C31H30Cl2FNO3 |
| Molecular Weight | 554.479 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1310 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1650 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
4740 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7010 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2390 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2150 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
4020 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5570 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
599.99 mg 1 times / day multiple, oral dose: 599.99 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
6020 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
4380 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5100 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
6.33 ng × eq/mL |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1040 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
9140 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
13600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
40400 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
61100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1630 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
15900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
13900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
36800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
42700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
599.99 mg 1 times / day multiple, oral dose: 599.99 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
50900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
43200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35840573/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
54100 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
16.6 ng × eq × h/mL |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.7 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
9.46 h |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMCENESTRANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:43:53 GMT 2025
by
admin
on
Wed Apr 02 08:43:53 GMT 2025
|
| Record UNII |
TBF1NHY02O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TBF1NHY02O
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
2114339-57-8
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
130232326
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
C174915
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
300000024164
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
11312
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY | |||
|
JK-174
Created by
admin on Wed Apr 02 08:43:53 GMT 2025 , Edited by admin on Wed Apr 02 08:43:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET->INHIBITOR, RECEPTOR DEGRADER |
ANTAGONIST
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
